MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Eric C. Kauffman (29, 30) showed that AZD8055/Ku0063794, a dual mTOR C1/C2 inhibitor, was more effective in Xp11.2 tRCC treatment, and its clinical trial results showed no significant cytotoxic side effects, representing a promising breakthrough in Xp11.2 tRCC treatment.